Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry

2021 ◽  
Author(s):  
Kota Sato ◽  
Kiyoshi Okazuka ◽  
Tadao Ishida ◽  
Jun Sakamoto ◽  
Shigeto Kaneko ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Multiparameter Flow Cytometry ◽  
Disease Detection ◽  
Single Tube ◽  
Minimal Residual Disease Detection ◽  
Minimal Residual

scholarly journals Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Takeshi Yoroidaka ◽  
Kentaro Narita ◽  
Hiroyuki Takamatsu ◽  
Momoko Fujisawa ◽  
Shinji Nakao ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Minimal Residual Disease ◽  
Plasma Cells ◽  
Residual Disease ◽  
Total Cell ◽  
Multiparameter Flow Cytometry ◽  
Single Tube ◽  
The Cost ◽  
Minimal Residual

AbstractIn this study, the minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method (DuraClone), which reduces the cost of antibodies and labor burden of laboratories, with the EuroFlow next-generation flow (NGF) method. A total of 96 samples derived from 69 patients with MM were assessed to determine the total cell acquisition number (tCAN), percentages of total and normal plasma cells (PCs), and MRD levels using two methods. We found that the tCAN was significantly higher with EuroFlow-NGF than with DuraClone (median 8.6 × 106 vs. 5.7 × 106; p < 0.0001). In addition, a significant correlation in the MRD levels between the two methods was noted (r = 0.92, p < 0.0001). However, in the qualitative analysis, 5.2% (5/96) of the samples showed discrepancies in the MRD levels. In conclusion, the DuraClone is a good option to evaluate MRD in multiple myeloma but it should be used with caution.

scholarly journals Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma

Haematologica ◽  
2020 ◽  
Vol 105 (10) ◽  
pp. e523
Author(s):  
Sandra Maria Dold ◽  
Veronika Riebl ◽  
Dagmar Wider ◽  
Marie Follo ◽  
Milena Pantic ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Multiparameter Flow Cytometry ◽  
Single Tube ◽  
Minimal Residual
Sign in / Sign up

Export Citation Format

Share Document